Compounded semaglutide

How is compounded semaglutide regulated?

Compounding lets a licensed pharmacist or physician combine or alter ingredients to build a medication tailored to one patient [1]. A 503A pharmacy may compound semaglutide only after a patient-specific prescription [4], and because compounded drugs are not FDA-approved, the agency does not verify their safety, effectiveness or quality before they reach a patient [1]. FDA has said unapproved GLP-1 drugs, including semaglutide, undergo no such review [3]. As of April 1, 2026, semaglutide is off the 503B bulks list and FDA's shortage list, and 503A enforcement discretion tied to that shortage has ended [2]. Compounded medications are not reviewed or approved by the FDA for safety or effectiveness.

What are the risks of compounded semaglutide?

FDA has logged multiple adverse events, some requiring hospitalization, tied to dosing errors from patients self-administering incorrect doses or clinicians miscalculating them [3]. Some compounders sell semaglutide salt forms, such as semaglutide sodium or semaglutide acetate, which FDA says are different active ingredients with no known lawful basis for compounding [3]. FDA also warns against any injectable GLP-1 drug that arrives warm or under-refrigerated, since improper shipping can affect quality [3]. Because pharmacies that are not outsourcing facilities are not required to report adverse events, FDA believes the true count is higher than the 990 reports logged for compounded semaglutide as of May 31, 2026 [3].